Cargando…

Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures

PURPOSE: The purpose of our study was to evaluate the influence of two PPIs (omeprazole (OME) and lansoprazole (LANSO)) on weakly basic anticancer drug doxorubicin (DOX) and pegylated liposomal doxorubicin (PLD) delivery to monolayer-cultured 4T1 murine breast cancer cells and tumor spheroids. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paškevičiūtė, Miglė, Petrikaitė, Vilma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877465/ https://www.ncbi.nlm.nih.gov/pubmed/31819614 http://dx.doi.org/10.2147/CMAR.S224097

Ejemplares similares

Differences of statin activity in 2D and 3D pancreatic cancer cell cultures
por: Paškevičiūtė, Miglė, et al.
Publicado: (2017)

Evaluation of low-intensity pulsed ultrasound on doxorubicin delivery in 2D and 3D cancer cell cultures
por: Paškevičiūtė, Miglė, et al.
Publicado: (2020)

Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures
por: Čeponytė, Ugnė, et al.
Publicado: (2018)

Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
por: Balandis, Benas, et al.
Publicado: (2021)

Comparative Study of Lipophilic Statin Activity in 2D and 3D in vitro Models of Human Breast Cancer Cell Lines MDA-MB-231 and MCF-7
por: Bytautaite, Meda, et al.
Publicado: (2020)

Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures
por: Daunys, Simonas, et al.
Publicado: (2019)

Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors
por: Yu, Man, et al.
Publicado: (2015)

The Chemo-Sensitizing Effect of Doxorubicin of Apple Extract-Enriched Triterpenic Complex on Human Colon Adenocarcinoma and Human Glioblastoma Cell Lines
por: Braciuliene, Aurita, et al.
Publicado: (2022)

3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs
por: Barbosa, Mélanie A. G., et al.
Publicado: (2021)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Novel N-Substituted Amino Acid Hydrazone-Isatin Derivatives: Synthesis, Antioxidant Activity, and Anticancer Activity in 2D and 3D Models In Vitro
por: Tumosienė, Ingrida, et al.
Publicado: (2021)

CHRONIC USE OF PROTON PUMP INHIBITORS AND THE QUANTITY OF G, D, AND ECL CELLS IN THE STOMACH
por: CAMILO, Silvia Maria Perrone, et al.
Publicado: (2020)

Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers
por: Toth, Jennifer M., et al.
Publicado: (2022)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Anticancer Activity of Sunitinib Analogues in Human Pancreatic Cancer Cell Cultures under Normoxia and Hypoxia
por: Skaraitė, Ieva, et al.
Publicado: (2023)

Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)
por: Nies, Anne T., et al.
Publicado: (2011)

Modulation of Induced Cytotoxicity of Doxorubicin by Using Apoferritin and Liposomal Cages
por: Gumulec, Jaromir, et al.
Publicado: (2014)

Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives
por: Srebro, Justyna, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Proton Pump Inhibitor-associated Mucosal Change
por: Kato, Mototsugu, et al.
Publicado: (2017)

Proton pump inhibitors induce hemolytic anemia
por: Al-Nasser, Asayil Nasser, et al.
Publicado: (2019)

When is proton pump inhibitor use appropriate?
por: Yadlapati, Rena, et al.
Publicado: (2017)

Use of proton pump inhibitors in general practice
por: Tosetti, Cesare, et al.
Publicado: (2017)

Effect of Proton Pump Inhibitors on Colorectal Cancer
por: Sasaki, Takamitsu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j65tqogopij961bend6uc5joml